PETER JUERGENSEN: Open Payments
NPI 1982699799 · NEW HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$864 in 37 payments from 16 companies in 2025. Trend: 2023 $812 · 2024 $525 · 2025 $864
Food & beverage: $862Education: $3
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 9 | $179 |
| Novo Nordisk Inc | 4 | $104 |
| Amgen Inc. | 3 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $63 |
| Otsuka America Pharmaceutical, Inc. | 2 | $59 |
| Ardelyx, Inc. | 3 | $57 |
| Mallinckrodt Hospital Products Inc. | 2 | $56 |
| AKEBIA THERAPEUTICS INC | 2 | $56 |
| Fresenius USA Marketing, Inc. | 2 | $45 |
| GlaxoSmithKline, LLC. | 2 | $38 |
Products named: Kerendia, JYNARQUE, IBSRELA, ACTHAR, Vafseo, VELPHORO, Ozempic, BENLYSTA.
Industry payments across CT — which companies pay providers there.
